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Letter to the editor
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Dear Editor,
Gestational Diabetes Mellitus (GDM)
complicates about 1 to 14 percent of
pregnancies (1), and pregnancy outcomes in
GDM are strongly related to glucose control
(2). Without treatment, GDM is associated
with fetal macrosomia and perinatal
complications (3). Insulin is commonly used
in patients who do not reach optimized
glycemic control with medical nutritional
therapy (4), because it is effective in[Electronic Physician 2010; 2: 81-84] Page 82
lowering the blood glucose as well as being
safe for both mother and fetus during
pregnancy (5-7). However, patients need
educating with regard to insulin injection
before they start using it, and there is also
always a chance of hypoglycemia in these
patients. Moreover, insulin resistance and
decreased insulin secretion are
pathophysiological mechanisms underlying
the development of GDM (8). These facts
have lead to increasing interest for the usage
of oral hypoglycemic agents in the treatment
of GDM(9). Patients prefer oral
hypoglycemic agents to insulin (10), and
oral agents are easier to administer than
insulin in clinical practice (11). However,
there are concerns that oral agents can cross
the placenta, and their role in fetal
teratogenesis and other fetal complications,
and in neonatal obesity and insulin
resistance, remains unclear (7, 12).
Metformin is an attractive option for
induction of ovulation in PCOS patients (13)
and is associated with a reduction in
gestational diabetes (14-18). The
pharmacokinetics of metformin in pregnant
women is similar to those in non-pregnant
patients (12). Metformin was found to be
readily transferable from the maternal to
fetal circuits across placentas that were
obtained from uncomplicated pregnancies
and pregnancies with GDM (12, 19). One
study showed that preeclampsia and prenatal
mortality are more common in patients who
were treated with metformin in comparison
with those treated with insulin (20).
However, other studies have contradicted
these findings (21). Potential hypoglycemic
agents have been shown to have no adverse
outcomes on neonates (22). Metformin may
have additional benefits, including reducing
insulin resistance, body weight, long term
risk of diabetes (23), and development of
GD. Metformin was not found to be
teratogenic, and did not adversely affect
birth length and weight, growth, or motor
social development in the first 18 months of
life (18).
Although metformin seems to be as effective
as insulin in management of patients with
GDM, while having many advantages over
insulin, there are still concerns about its
safety in neonates. Randomized controlled
trials assessing metformin safety in neonates
and long-term follow-up of these neonates is
lacking. Insulin is still the drug of choice in
management of GDM but long-term follow-
up of metformin effects on neonates could
change this role and may revolutionize the
management of GDM. In the mean time, we
should consider that specific patients such as
PCOS and patients with severe insulin
resistance (24) may benefit more than others
from metformin. Consequently, studies
should be carried out on specific patients in
order to establish criteria for usage of
metformin or insulin in GDM.
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